After a Landmark Ruling, Bayer's True Test Lies in a Missouri Courtroom on July 9
28.06.2026 - 23:27:53 | boerse-global.de
The 23 percent surge in Bayer’s shares last week was as dramatic as it was decisive. By Friday’s close, the stock had settled at €46.61, powered by a US Supreme Court decision that fundamentally alters the legal landscape for Roundup. The ruling, handed down on June 25, 2026, held — by a 7-to-2 majority in Durnell — that Monsanto cannot be held liable under state law for failing to include cancer warnings on glyphosate products as long as the EPA itself does not require such labels. The principle of federal preemption now bars individual states from imposing divergent warning obligations.
Investors cheered the move as a structural blow against a sprawling litigation overhang. But the euphoria masks an uncomfortable truth: the Court’s decision eliminates a category of claims but leaves the most expensive legal battle — a proposed $7.25 billion settlement — still dangling in front of a Missouri judge. The hearing scheduled for July 9 in St. Louis will determine whether the agreement receives final court approval and whether enough plaintiffs accept the terms to make it stick.
The settlement: a $7.25 billion gamble on plaintiff buy-in
Bayer struck the comprehensive settlement in February 2026 to resolve roughly 200,000 pending Roundup lawsuits. A federal judge earlier rejected an attempt to move the case to a federal venue, sending it back to Missouri state court — a procedural win that keeps the process on a clear track. But the deal is not yet sealed. On July 9, the court will hear arguments on final approval, and the outcome hinges on the opt-out rate among plaintiffs. If too many reject the terms, the entire agreement could unravel.
Jefferies analyst Michael Leuchten has cautioned that the path to a clean resolution is anything but smooth. Some plaintiff attorneys have already voiced sharp criticism of the settlement’s structure, and the judge’s ruling on whether the terms are fair and adequate will be closely watched. A successful close would remove the largest single source of uncertainty from Bayer’s balance sheet, allowing the net financial debt — which stood at over €32.5 billion at the end of March — to begin a meaningful descent.
Should investors sell immediately? Or is it worth buying Bayer?
Cash flow: the real weight on the balance sheet
Even if the settlement holds, Bayer’s financial strain is far from over. Free cash flow in the first quarter of 2026 was negative €2.32 billion, compared with negative €1.53 billion a year earlier, driven by payments for PCB and glyphosate litigation. CFO Wolfgang Nickl — who will hand over the reins to Judith Hartmann on June 1 — has forecast total legal cash outflows of roughly €5 billion for the full year. That drag is expected to push free cash flow into a range of negative €2.5 billion to negative €1.5 billion.
The debt load is structural, not cyclical. Net financial debt may actually climb to between €32 billion and €33 billion by year-end. Without a sharp improvement in operating cash generation, the post-ruling stock rally lacks a fundamental anchor. The market is now waiting for concrete evidence that the legal relief will translate into a sustainable reduction in leverage.
Pipeline promise: Asundexian and Nubeqa offer a potential offset
On the pharmaceutical side, Bayer has two cards to play. Nubeqa (darolutamide) continues to gain traction, with over 200,000 patients treated worldwide and three approvals in prostate cancer across the US and Europe. More critical is Asundexian, a first-in-class oral factor XIa inhibitor for stroke prevention. The pivotal phase III OCEANIC-STROKE trial showed a 26 percent reduction in ischemic strokes compared with placebo, with no increase in bleeding risk.
Regulatory momentum is building fast. The US FDA granted priority review in May 2026, Chinese authorities awarded a priority review as well, and the EMA has initiated its central assessment. If all three approvals come through, Bayer would bring the first FXIa inhibitor to market, potentially leapfrogging the competing Milvexian being developed by Bristol Myers Squibb and Johnson & Johnson. A clean sweep on Asundexian would provide a multi-billion-dollar revenue stream that could gradually offset the cash drain from litigation.
Technical trouble: an overheated chart
The stock’s breakneck advance has pushed the relative strength index to 80.6 — deep into overbought territory. The share price now trades roughly 23 percent above its 50-day moving average and 27.4 percent above the 200-day average. After a single-week gain of 23 percent, profit-taking pressure is building. The next resistance level sits at the 52-week high of €49.93. A failure at that mark, combined with negative news from Missouri, could trigger a sharp reversal.
Bayer at a turning point? This analysis reveals what investors need to know now.
What comes next: two pivotal events in close succession
Beyond the July 9 hearing, the next major catalyst is Bayer’s second-quarter earnings, expected in early August. The company has announced a quiet period from July 15 to August 4. After that, new CFO Judith Hartmann will present an updated outlook on debt and free cash flow — the first such update following the Supreme Court ruling. Investors will scrutinize whether management can translate legal relief into a credible path toward positive free cash flow.
For now, the bull case rests on two pillars: a smooth settlement approval in St. Louis and continued regulatory momentum for Asundexian. If both hold, the stock could test the €50 mark. If either falters, the RSI leaves little room for patience. The Supreme Court handed Bayer a historic legal victory — but the next few weeks will decide whether that victory becomes a lasting valuation reset or just a spectacular relief rally.
Ad
Bayer Stock: New Analysis - 28 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
